



## Review

## Fighting disease by selective autophagy of aggregate-prone proteins

Helene Knævelsrud, Anne Simonsen \*

Institute of Basic Medical Sciences, University of Oslo, P.B. 1112 Blindern, 0317 Oslo, Norway

## ARTICLE INFO

## Article history:

Received 25 February 2010

Revised 9 April 2010

Accepted 15 April 2010

Available online 20 April 2010

Edited by Stefan Hohmann

## Keywords:

Autophagy

Neurodegeneration

p62

Proteinopathies

Aggregate-prone protein

Huntingtin

## ABSTRACT

**Ubiquitinated protein aggregates are hallmarks of a range of human diseases, including neurodegenerative, liver and muscle disorders. These protein aggregates are typically positive for the autophagy receptor p62. Whereas the ubiquitin-proteasome system (UPS) degrades shortlived and misfolded ubiquitinated proteins that are small enough to enter the narrow pore of the barrel-shaped proteasome, the lysosomal pathway of autophagy can degrade larger structures including entire organelles or protein aggregates. This degradation requires autophagy receptors that link the cargo with the molecular machinery of autophagy and is enhanced by certain posttranslational modifications of the cargo. In this review we focus on how autophagy clears aggregate-prone proteins and the relevance of this process to protein aggregate associated diseases.**

© 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

### 1. Introduction


Accumulation of ubiquitinated protein aggregates accompanies several neurodegenerative disorders, as well as a number of other protein aggregation diseases (proteinopathies) including those affecting muscles, heart and liver. These aggregates consist of misfolded or aggregate-prone mutated versions of normal proteins, exemplified by the cytotoxic polyglutamine-expanded huntingtin protein causing Huntington's disease (HD). A well-characterized pathway for the cell to degrade misfolded proteins is through the ubiquitin-proteasome system (UPS), where misfolded proteins are tagged with ubiquitin and targeted to the proteasome for degrada-

tion. However, aggregate-prone proteins are poor substrates for proteasomal degradation as proteins must pass through the narrow barrel-shaped proteasome to be degraded [1,2]. Recent studies have shown that also autophagy, a lysosomal degradation pathway for intracellular material, can degrade misfolded proteins. There are three different types of autophagy: chaperone-mediated autophagy (CMA), microautophagy and macroautophagy. CMA involves direct import of cytosolic proteins that contain a pentapeptide motif recognized by a chaperone leading to translocation into the lysosomes [3]. Microautophagy involves direct uptake of cytoplasmic components by invagination of the lysosomal membrane [4]. Macroautophagy (hereafter referred to simply as autophagy) involves expansion of a phagophore membrane which engulfs cytoplasmic material as it closes to form a double-membrane vesicle, the autophagosome (Fig. 1). After its formation, the autophagosome can mature by fusion with endosomes to form amphisomes prior to fusion with lysosomes or fuse directly with lysosomes to form the degradative autolysosomes. There the originally cytoplasmic contents are degraded and the resulting macromolecules are released to be reused by the cell. The core molecular machinery of macroautophagy was first elucidated by elegant genetic studies in yeast [4,5] and has later been progressively characterized in mammals. The proteins found in the initial screens are named autophagy-related (Atg) proteins. Although the core autophagy machinery is well conserved from yeast to mammals, differences exist and this review will mainly focus on mammalian autophagy. Autophagy is induced by stresses like starvation, to make the cell recycle its contents in attendance of replenished nutrient supplies. In addition to this

**Abbreviations:** A $\beta$ , amyloid- $\beta$ ; AD, Alzheimer disease; Alf, autophagy-linked FYVE protein; ALIS, aggresome-like inducible structure; ALS, amyotrophic lateral sclerosis; APP, amyloid precursor protein; Atg, autophagy-related; Bchs, blue cheese; CMA, chaperone-mediated autophagy; COPI, coat protein complex I; CBP, CREB-binding protein; Cvt, cytoplasm to vacuole targeting; DOR, diabetes- and obesity-regulated gene; ESCRT, endosomal sorting complex required for transport; FTD, frontotemporal dementia; HD, Huntington's disease; HDAC6, Histone deacetylase 6; IF, intermediate filament; LC3, MAP1 light chain 3; LIR, LC3-interacting region; MDB, Mallory-Denk body; MTOC, microtubule-organizing centre; mTOR, mammalian Target of Rapamycin; MVB, multivesicular body; NBR1, neighbour of BRCA1 gene 1; NES, nuclear export signal; NLS, nuclear localization signal; PD, Parkinson's disease; PE, phosphatidylethanolamine; PI3K, phosphatidylinositol 3-kinase; PI3P, phosphatidylinositol-3-phosphate; PML, promyelocytic leukemia; ROS, reactive oxygen species; SCA1, spinocerebellar ataxia 1; TDP-43, TAR DNA binding protein-43; UBA, ubiquitin-associated domain; ULK, unc-51-like kinase; UPS, ubiquitin-proteasome system

\* Corresponding author. Fax: +47 22851058.

E-mail address: [anne.simonsen@medisin.uio.no](mailto:anne.simonsen@medisin.uio.no) (A. Simonsen).



**Fig. 1.** Autophagy in mammalian cells. When autophagy is induced a phagophore membrane nucleates and expands to form an autophagosome, thereby engulfing part of the cytoplasm, including cytosolic proteins, organelles and aggregated proteins. The autophagosome may fuse directly with lysosomes or mature by fusion with different endocytic compartments (early endosomes, multivesicular bodies and late endosomes) to form amphisomes containing both autophagosomal and endosomal content. The early endosome is a sorting compartment from where internalized cargo like nutrient receptors cycles back to the plasma membrane, whereas cargo destined for degradation is sorted into the intraluminal vesicles of forming multivesicular bodies (MVBs). These MVBs then mature into late endosomes, which fuse with lysosomes for the final degradation of the internalized contents. This stepwise maturation of the endocytic compartments is associated with decreasing pH throughout the pathway. Fusion of autophagosomes with each of these endocytic compartments also supports a stepwise fusion model of autophagosome maturation. Finally the autophagosomes or amphisomes fuse with lysosomes where the originally cytoplasmic material becomes degraded and the resulting macromolecules recycled back to the cytosol to be reused by the cell.

direct pro-survival effect, over the past years it has been discovered that autophagy plays essential roles in development, immunity and prevention of disease [6,7].

## 2. A brief introduction to the molecular core machinery of autophagy

The mammalian autophagic machinery has already been extensively reviewed [8,9] and only the main components are described here. In brief, the nucleation and expansion of autophagic membranes requires four groups of proteins: (1) the Atg1/unc-51-like kinase (ULK) complex, (2) the Vps34/class III phosphatidylinositol 3-kinase (PI3K) complex I, which forms phosphatidylinositol-3-phosphate (PI3P), (3) the transmembrane protein mAtg9 and its associated cycling machinery and (4) the two ubiquitin-like proteins Atg12 and Atg8/MAP1 light chain 3 (LC3) and their conjugation systems.

### 2.1. Nucleation

The induction of autophagy is directly inhibited by the mammalian Target of Rapamycin (mTOR) complex, which coordinates cell

growth and autophagy [10]. mTOR activity is regulated by amino acid and glucose levels and is inhibited by starvation. In the presence of sufficient nutrients supplied, mTOR phosphorylates ULK1 and Atg13, thus inactivating the ULK1 complex [10]. But when mTOR is inhibited by starvation or treatment with the drug rapamycin, the ULK1 complex is activated and nucleation of autophagic membranes can proceed. The nucleation additionally requires the Vps34/class III PI3K complex I, which phosphorylates phosphatidylinositol to create PI3P [8]. Finally, the integral membrane protein mAtg9 must be recruited to the site of phagophore nucleation [9]. The precise origin of the membranes composing the phagophore is still under debate. But PI3P-positive structures, called omegasomes, have been found to form from the endoplasmic reticulum (ER) and newly formed autophagosomes seem to escape from these [11].

### 2.2. Expansion

Next, the phagophore expands and finally close to form the autophagosome. Two ubiquitin-like conjugation systems are required for this expansion [12]. Analogous to ubiquitination, the ubiquitin-like proteins Atg12 and LC3 are activated by an E1-like

enzyme (Atg7) and conjugated by an E2-like enzyme (Atg10 and Atg3, respectively) to Atg5 or phosphatidylethanolamine (PE), respectively. The Atg12–Atg5 conjugate associates with membrane-bound Atg16L to form a high molecular-weight complex. Atg12–Atg5 works in an E3-like fashion for the conjugation of LC3 to PE [13] and the Atg12–Atg5–Atg16L complex determines the sites of LC3 lipidation [14]. Before LC3 can enter the conjugation pathway it has to be cleaved at its C-terminus to expose a glycine residue. This cleavage is done by the cysteine protease Atg4 and the resulting cytosolic protein is called LC3-I. The PE-conjugated LC3 is called LC3-II. LC3-II was found to mediate membrane tethering and hemifusion and likely contributes to phagophore expansion, and it might also assist the final fusion to close the autophagosome [15]. The proteins required for nucleation and expansion of autophagic membranes are retrieved from the forming autophagosome, with the exception of LC3. LC3-II is inserted into both leaflets of the forming autophagosome. Whereas LC3-II on the outer leaflet is retrieved through delipidation by Atg4, LC3-II on the inner leaflet remains bound to autophagic membranes throughout the pathway and thus serves as an autophagic marker protein.

### 2.3. Maturation

After its final closure, the autophagosome matures by fusion with endocytic compartments, creating amphisomes [16], but autophagosomes may also fuse directly with lysosomes. Both the coat protein complex I (COPI) and the endosomal sorting complex required for transport (ESCRT) have been shown to be required for maturation of autophagosomes [17–19]. COPI is found at early endosomes which function as a sorting station for endocytic cargo, whereas ESCRTs are required for formation of multivesicular bodies (MVB) and sorting of endocytic cargo targeted for lysosomal degradation into MVBs. The fusion of autophagosomes with both of these endocytic compartments supports a stepwise fusion model or vesicle maturation [20], where each fusion step delivers components facilitating further fusion steps (Fig. 1). As described above, the Vps34/class III PI3K complex I is involved in nucleation of autophagic membranes, but Vps34 can also engage in a related complex, Vps34/class III PI3K complex II, which regulates the maturation of autophagosomes [8]. Moreover, the endosomal PI3P 5-kinase PIKfyve, has been shown to be involved in this maturation [21,22], indicating that also endocytic membrane lipids are important for proper autophagosome maturation.

Autophagosomes can form all over the cell cytoplasm, but must traffic to the perinuclear area to fuse with lysosomes, a process shown to depend on microtubules and dynein [23–25]. This trafficking is especially important in neurons, where the site of autophagosome formation might be located far from the lysosomes. Autophagosomes or amphisomes tether, dock and fuse with lysosomes. Among others, the class C Vps complex, as well as Rab7 and Rab11 are involved in the fusion of autophagic vesicles with lysosomes [26–29]. Recently, the Rab7-, PI3P- and LC3-binding protein FYCO1 was found to promote microtubule plus end-directed transport of autophagosomes [30], thereby connecting transport of autophagosomes to the fusion with lysosomes.

## 3. Aggrephagy – selective autophagy of protein aggregates

### 3.1. Protein aggregates

Commonly observed human neurodegenerative diseases can be subdivided into groups based on the predominant type of aggregate-prone protein, such as tauopathies, synucleinopathies, polyglutamine-containing inclusions or TAR DNA binding protein-43 (TDP-43) proteinopathies. Moreover, aggregates are often struc-


tured (amyloid) or amorphous and are typically composed of insoluble proteins that can be hyperphosphorylated and crosslinked. Aggregate-prone proteins are thought to form microaggregates that can be combined and deposited into larger aggregates of various size and structure. In mammalian cells, aggregated proteins can be trafficked by microtubule-dependent retrograde transport to a perinuclear site of aggregate deposition called the aggresome (Fig. 2). It has been proposed that aggresomes could be a long-term storage solution for misfolded proteins waiting to be degraded by autophagy [31] and their formation could enhance the efficiency and selectivity of autophagic degradation of aggregated proteins. However, not all kinds of protein inclusions or aggresomes can be degraded by autophagy [32].

Aggregate-prone proteins are associated with cytotoxicity. In addition to no longer performing their wild-type function, the observed toxicity is thought to be a gain of function of these mutant proteins [33]. The exact nature of the cytotoxic species is still debated. Longer polyglutamine tracts in the aggregate-prone protein huntingtin correlate with earlier onset of the associated disease and higher aggregate propensity of mutant proteins [34]. This has been taken as proof that it is the aggregates that are the cytotoxic species. Others argue that soluble oligomers or small oligomers are more toxic and that aggresome or inclusion body formation protects the cells from these toxic species [35,36].

Whether entire protein aggregates are directly degraded by autophagy, or if autophagy rather degrades soluble aggregate precursors is still debated. Autophagy has also been implicated in the dissolution of larger neuronal inclusions into smaller aggregates [37]. If soluble aggregate precursors are removed by autophagy, then the aggregates could also disappear because the equilibrium would be shifted away from aggregate formation towards aggregate dissolution [33]. However, protein aggregates larger than 1 µm have also been observed inside autophagic membranes [38], indicating that the autophagic machinery can sometimes degrade entire aggregates. In this case, it is not known whether the aggregates are sequestered by preexisting autophagic membranes or if the autophagic machinery is recruited to the aggregates to mediate local assembly of autophagic membranes around the aggregate.

### 3.2. Selective autophagy

During starvation, autophagy is induced to recycle cellular components and support cell survival until nutrients are replenished. Therefore starvation-induced autophagy is thought to be a non-specific process, randomly sequestering cytoplasmic components [39]. However, autophagy also proceeds at basal levels, performing important quality control functions by removing damaged organelles and other substrates targeted for lysosomal degradation. It has recently become evident that this basal autophagy involves selective recognition of the autophagic cargo. The autophagic degradation of mitochondria has been termed mitophagy, whereas autophagic degradation of intracellular pathogens is known as xenophagy. For autophagy-mediated clearance of protein aggregates, the term aggrephagy was coined by the group of Seglen and co-workers [40]. Selective autophagy pathways are also present in yeast. Among these, the cytoplasm to vacuole targeting (Cvt) pathway is a biosynthetic pathway that delivers the hydrolase aminopeptidase I to the vacuole. Although not present in mammals, the Cvt pathway can serve as a model for selective autophagy also in higher organisms [41]. The key factors are cargo receptors that connect the cargo to the core autophagy machinery. Also in mammalian cells, the specific targeting of mitochondria, pathogens or protein aggregates raises the question of how the autophagic machinery recognizes these substrates. At least part of the answer lays in the recent discovery of proteins functioning



**Fig. 2.** Degradation of protein aggregates by autophagy. Newly synthesized proteins normally fold into functional proteins. However, in the case of misfolding, chaperones can sometimes help refold the protein into its native conformation, but misfolded proteins are often targeted for degradation. K48-linked ubiquitination targets the misfolded protein for degradation by the proteasome. There the proteins are unfolded to pass through the narrow pore of the barrel-shaped proteasome and the ubiquitin moieties are recycled. Misfolded aggregate-prone proteins can also be degraded by autophagy or deposited at the aggresome. These two options are associated with K63-linked ubiquitination. For transport to the aggresome, the ubiquitinated proteins are recognized by HDAC6 and transported along the microtubules in a dynein-dependent manner. The aggresome thus protects the cell from the toxicity of aggregate-prone proteins and possibly facilitates the autophagic degradation of these proteins. For degradation by autophagy, the autophagy receptors p62 and NBR1 bind to ubiquitinated proteins and self-polymerize through their PB1 domains to form p62 bodies. p62 interacts with the autophagic protein LC3 through its LIR and then, in collaboration with the large PI3P-binding protein Alfy, promotes the degradation of these protein aggregates. p62 and Alfy are also found in PML bodies in the nucleus and shuttle between the nucleus and the cytoplasm. In the nucleus, p62 is proposed to recruit proteasomes to nuclear aggregates to facilitate their degradation.

as autophagy receptors, linking the autophagic machinery to its substrates. These autophagy receptors contain an LC3-interacting region (LIR), mediating interaction with Atg8/LC3 family members (LC3/GABARAP/GATE-16) and a domain recognizing the specific substrate. Such autophagy receptors have been identified for the degradation of ubiquitinated bacteria (NDP52) [42] and mitochondria (NIX) [43], as well as for ubiquitinated protein aggregates (p62 and NBR1, described below) [44–46].

In addition to these aggrephagy-specific autophagy receptors, aggrephagy relies in general on the same molecular core machinery as non-specific starvation-induced autophagy. Neuron-specific Atg5 or Atg7 knock-out mice accumulate ubiquitinated cytoplasmic inclusion bodies [47,48] and studies in flies have shown that ubiquitinated and p62-positive aggregates accumulate in the absence of the Vps34/PI3K regulator Vps15 or Atg8/LC3 [49–51]. Likewise, siRNA-mediated clearance of Vps34/PI3K itself or its complex partner Beclin 1, inhibited autophagic clearance of an aggregate-prone model protein and the same effect was observed by treating these cells with Vps34/PI3K inhibitors [52]. In sum-

mary, the Atg5 and LC3 conjugation systems, as well as the Vps34/PI3K complex are required for autophagic degradation of protein aggregates. However, autophagic clearance of an aggregate-prone model protein can proceed even in the presence of active mTOR [52], indicating that aggrephagy is regulated differently than starvation-induced autophagy. For instance has insulin signalling, known to activate mTOR, been shown to lead to clearance of aggregate-prone proteins [52].

### 3.3. p62 and NBR1

p62 and neighbour of BRCA1 gene 1 (NBR1) have a very similar domain structure, with NBR1 being the larger of the two [53]. Both p62 and NBR1 are themselves substrates of autophagy and are continuously degraded [44–46]. This requires their LIR motif, which interacts with LC3 and explains how p62 and NBR1 function as cargo receptors for autophagy. Their recognition of ubiquitinated protein aggregates is mediated through the C-terminal ubiquitin-associated domain (UBA). Finally, they both contain an



oligomerization domain (PB1) through which they can homo- or hetero-oligomerize or interact with atypical protein kinase C isoforms and other binding partners [53]. In addition to being a cargo receptor for protein aggregates, p62 has been proposed to act as a cargo receptor for other ubiquitinated substrates, like ubiquitinated midbody remnants after mitosis [54] and ubiquitinated intracellular bacteria [55]. Besides its role in autophagy, p62 acts as an important scaffold or adaptor protein in other signalling pathways, like NF- $\kappa$ B signalling [56] and Nrf2-induced expression of anti-oxidative response genes [57].

p62 (and NBR1) is required for the formation of ubiquitinated protein aggregates (Fig. 2), also called p62 bodies, sequestosomes or aggresome-like inducible structure (ALIS) [45,58,59] mediated by its self polymerization and ubiquitin binding. These structures contain misfolded ubiquitinated proteins and can be experimentally induced by addition of the translational inhibitor puromycin [60]. Sequestration of misfolded proteins into such aggregates might prevent the misfolded, often toxic proteins from harming other cellular proteins until they become degraded by autophagy or the proteasome [59]. As described above, inhibition of autophagy in mouse brain or liver by knockout of the *Atg5* or *Atg7* genes, causes ubiquitinated protein inclusions to accumulate [47,48,61]. *Atg7*<sup>−/−</sup>/*p62*<sup>−/−</sup> mice have much less ubiquitinated protein inclusions than *Atg7*<sup>−/−</sup> mice, showing that p62 is involved in formation of the observed aggregates [62]. This is probably because in the absence of autophagy, p62 accumulates and sequesters ubiquitinated proteins through its UBA domain, including those that would normally be degraded by the UPS [63]. Interestingly, the combined removal of p62 and *Atg7* in hepatocytes and neurons attenuated liver impairment caused by autophagy deficiency, but had little effect on neurodegeneration. p62 knockout mice show normal autophagy and do not accumulate protein inclusions compared to wild-type controls [62]. These effects might seem to contradict the role of p62 in aggregate clearance, but can be explained by its aggregate-promoting role. The lack of a significant phenotype in these mice can also be explained by the redundant function of NBR1. Corresponding to autophagy-deficient mice, autophagy-deficient fruit flies show accumulation of ubiquitinated protein aggregates [50,51,64]. These aggregates are positive for the *Drosophila* orthologue of p62, Ref(2)P, and the aggregates disappear in autophagy and *Ref(2)P* double mutants [51].

p62 is also a common component of ubiquitinated protein inclusions found in human diseases, including Lewy bodies (Parkinson's disease (PD)), neurofibrillary tangles (Alzheimer disease (AD)), Huntingtin aggregates (HD) and Mallory bodies (alcoholic and nonalcoholic steatohepatitis) [65,66]. Immunostaining of p62 on histological samples can be employed as a diagnostic marker for human degenerative diseases associated with protein aggregates [67] and it will be interesting to learn whether accumulation of p62 in these diseases is associated with dysfunctional autophagy.

### 3.4. Alfy

In addition to p62 and NBR1, the large protein Alfy (autophagy-linked FYVE protein, also known as WDFY3) is involved in degradation of protein aggregates by autophagy (Fig. 2). Alfy becomes recruited from the nucleus to cytoplasmic ubiquitinated protein aggregates also containing autophagic membrane markers upon cellular stress like starvation and proteasome inhibition [68]. Alfy was recently shown to interact directly with p62 and, similar to p62 and NBR1, be required to recruit ubiquitinated proteins into aggregates that become degraded by autophagy [69]. Alfy is a large scaffolding protein containing several domains which can facilitate recruitment of the autophagic machinery to the protein aggregates; a PH domain, a p62-interacting BEACH domain [69], a

PI3P-binding FYVE domain [68] and WD40-repeats engaged in interaction with Atg5 [38]. In line with these results, it was recently found that Alfy is recruited to intracellular inclusions where it scaffolds a complex containing p62 and the autophagic effectors Atg5, Atg12, Atg16 and LC3. Whereas loss of Alfy was found to inhibit inclusion clearance, its overexpression caused elimination of aggregates in an Atg5-dependent manner, and led to protection in a neuronal and *Drosophila* model of polyglutamine toxicity [38]. These results corroborate previous studies reporting that fruit flies mutant for the Alfy homologue, *blue cheese* (Bchs), show reduced life span due to accumulation of ubiquitinated protein aggregates in the brain [70]. It is not known if Alfy can recognize the ubiquitinated aggregates directly or if it is recruited through its interaction with p62.

### 3.5. HDAC6

Autophagy and the UPS both target misfolded proteins for degradation. Proteolytic cross-talk clearly exists between the two pathways, shown by autophagy acting as a compensatory degradation system when the UPS is blocked [71,72]. Histone deacetylase 6 (HDAC6), a tubulin deacetylase that binds ubiquitin via its C-terminal BUZ-domain, was shown to mediate this effect, probably by bringing proteins that would otherwise accumulate to the autophagic machinery. Overexpression of HDAC6 in a fly model of neurodegenerative disease (Spinobulbar muscular atrophy caused by polyglutamine repeat expansion in the androgen receptor), accelerated the degradation of the mutant aggregate-prone protein by autophagy and protected the flies from neurotoxicity [71]. HDAC6 is required for the formation of aggresomes by transporting misfolded proteins to the microtubule-organizing centre (MTOC) along microtubules through interaction with dynein [73,74] (Fig. 2). HDAC6 is also thought to mediate the transport of components of the autophagic machinery to the aggresome, thus bringing the machinery close to its substrates [72]. Recently, HDAC6 was also found to promote the creation of an actin network that enhances the fusion of autophagosomes and lysosomes [75]. This effect was specific to basal quality-control autophagy and dispensable for starvation-induced autophagy.

## 4. Regulation of autophagic degradation of protein aggregates

The degradation of aggregate-prone proteins by autophagy can be regulated both at the level of the autophagic machinery and at the level of the aggregates, but not much is known about this regulation. As mentioned above, aggrephagy seems to proceed independent of mTOR signalling and might be regulated by insulin signalling [52]. Reactive oxygen species (ROS), known to accumulate by age, has been found to inactivate Atg4, thus inhibiting LC3 delipidation and potentially promoting autophagy [76]. However, although a clear correlation was found between reduced autophagy levels, formation of ubiquitinated protein aggregates and sensitivity to oxidative stress in *Drosophila* [50], further studies are required to elucidate how ROS, as well as the p62-mediated Nrf2-induced anti-oxidant response [57], regulates aggrephagy and disease progression.

Several proteins of the autophagic machinery localize to the nucleus and undergo nucleocytoplasmic shuttling to exert their function in the cytoplasm. Very little is known about how this nucleocytoplasmic shuttling affects autophagy and no thorough study of which of the autophagy associated proteins rely on nucleocytoplasmic shuttling have been performed. Concerning the aggregates, various post-translational modifications, like ubiquitination, acetylation and phosphorylation, have been shown to specifically enhance the degradation of the aggregate-prone proteins by autophagy.

#### 4.1. Nucleocytoplasmic shuttling

The nucleus and cytoplasm are separated by the nuclear envelope. Small water-soluble molecules and proteins smaller than ~40 kDa can freely diffuse between the compartments through the nuclear pores, whereas larger proteins must actively be transported. Nuclear import is usually mediated by importin- $\alpha$  binding to a nuclear localization signal (NLS) and nuclear export by exportin-1/CRM1 binding to a nuclear export signal (NES) of the shuttling protein. The assembly and disassembly of these complexes is mediated by the GTP/GDP-bound status of the small GTPase Ran [77].

The autophagic proteins found to undergo nucleocytoplasmic shuttling so far are Beclin 1, diabetes- and obesity-regulated gene (DOR), p62 and Alfy. The former two are required for starvation-induced autophagy, whereas the latter two are implicated in more specific forms of autophagy as described above. The first autophagic protein shown to rely on nucleocytoplasmic shuttling was Beclin 1 [78]. Beclin 1 is part of the PI3K complex and has a tumor suppressive function [79]. It contains a NES motif which is required for Beclin 1 to promote starvation-induced autophagy and inhibit tumorigenicity [78]. Recently also DOR, a reported nuclear cofactor of thyroid hormone receptors, was implicated in autophagy [80]. Upon starvation, DOR exits the nucleus to interact with LC3 family members in the cytoplasm and promote autophagy [80]. Mutation of the DOR NES motif restricted DOR to the nucleus even under stress conditions and blocked induction of autophagy by rapamycin.

Alfy localizes to the nucleus and nuclear envelope in HeLa cells, but is redistributed to protein bodies in the cytoplasm upon starvation or proteasomal inhibition [68]. In contrast to the predominant nuclear localization of Alfy, p62 is found to shuttle continuously between the nucleus and the cytosol at a high rate [81]. p62 was recently found to interact directly with Alfy and to be required to recruit Alfy from the nucleus to the cytoplasmic ubiquitinated protein bodies [69]. This recruitment of Alfy from the nucleus is essential for autophagic degradation of larger complexes of ubiquitinated proteins. p62 contains two NLS and one NES motifs, and the shuttling of p62 is modulated by its phosphorylation and aggregation status. At steady state, the majority of the p62 pool is found in the cytoplasm, but this is rapidly changed by inhibition of nuclear export [81]. Interestingly, most nuclear autophagy proteins identified to date were found to localize to promyelocytic leukemia nuclear bodies (PML-NBs), especially when exportin-1/CRM1-dependent nuclear export was inhibited. PML nuclear bodies have been associated with a broad spectrum of nuclear processes, as transcription, DNA repair, stress, proteolysis and apoptosis [82]. The nuclear proteasome-mediated protein degradation occurs at a subset of PML-NBs [83]. Both p62 and Alfy localize to PML nuclear bodies and are required for the recruitment of ubiquitinated proteins to these nuclear bodies [69] (Fig. 2). p62 has been suggested to facilitate proteasome recruitment to these sites and thereby help the degradation of nuclear ataxin-1 aggregates [81] (Fig. 2). However, it cannot be excluded that p62 and Alfy export ubiquitinated substrates to the cytoplasm for degradation by the autophagic machinery. It will also be interesting to learn whether the nuclear autophagic proteins undergo some kind of regulation or modification at the PML-NBs.

#### 4.2. Ubiquitination

Several post-translational modifications of aggregated proteins have been found to enhance their degradation through autophagy. First, protein aggregates targeted by autophagy are generally ubiquitinated. Ubiquitin chains come in different flavours depending on through which lysine residue the ubiquitin moieties are linked.

K48-linked ubiquitin chains are a classical signal for degradation via the UPS. It is not clear if autophagic degradation is signalled through a specific ubiquitin-link. However, p62 and NBR1 have been shown to preferentially recognize K63-linked ubiquitin chains [46,84,85] and inclusions labelled with K63-linked ubiquitin chains have been associated with autophagic degradation [86]. Furthermore, HDAC6 also preferentially binds K63-linked ubiquitin chains *in vivo* [87]. p62 is also known to interact with the E3 ubiquitin ligase TRAF6, which catalyzes K63 polyubiquitination [56] and it is thus likely that TRAF6 could contribute to the ubiquitination of protein aggregates degraded by autophagy. Thus, cargo modified with K63-linked ubiquitination might therefore be preferentially targeted to the autophagic degradation pathway. Actually, ubiquitination alone might be sufficient for autophagic targeting via p62. Indeed, peroxisomes or a cytosolic model protein (red fluorescent protein) tagged with ubiquitin became targeted for autophagic degradation in a p62-dependent manner [88].

#### 4.3. Acetylation

Acetylation of mutant aggregate-prone huntingtin enhances its degradation by autophagy [89]. In contrast, mutant huntingtin that is resistant to acetylation strongly accumulates in the expressing cells. Huntingtin is actually a nuclear protein and must be exported to the cytoplasm to be degraded by autophagy. The described acetylation is performed by nuclearly localized CREB-binding protein (CBP), but it is not clear if the acetylation enhances the nuclear export of the mutant huntingtin or its actual degradation by the autophagic machinery in the cytoplasm. It will be interesting to learn if also other proteins can be targeted for lysosomal degradation through acetylation.

#### 4.4. Phosphorylation

In addition to acetylation, it was recently reported that phosphorylation by the IKK complex also enhances degradation of mutant aggregate-prone huntingtin [90]. Phosphorylation of huntingtin was found to regulate other post-translational modifications like ubiquitination, SUMOylation and acetylation. The increased degradation of phosphorylated huntingtin proceeded both through the proteasome and the lysosome. However, in this study IKK-mediated phosphorylation was more efficient for wild-type than mutant huntingtin, suggesting that the phosphorylation-driven clearance of mutant huntingtin is reduced. Previously it has been found that phosphorylation of mutant aggregate-prone polyglutamine proteins (ataxin-1, ataxin-3 and huntingtin) also regulate their ability to get cleaved, aggregate and cause neurodegeneration [91–96].

### 5. Autophagic degradation of aggregate-prone proteins in disease

Basal autophagy is especially important in post-mitotic cells like neurons and hepatocytes, which cannot get rid of their waste through cell division. As previously discussed, inhibition of autophagy in mouse brain or liver by knockout of the *Atg5* or *Atg7* genes, causes ubiquitinated protein inclusions to accumulate [47,48,61]. Importantly, brain-specific suppression of autophagy causes neurodegeneration even in the absence of aggregate-prone disease-associated mutant proteins, showing that basal quality-control autophagy is important to prevent neurodegeneration [47,48]. Several neurodegenerative phenotypes are associated with accumulation of protein inclusions, including polyglutamine diseases, PD, frontotemporal dementia (FTD) and AD. Autophagy has been implicated in all of these diseases.

### 5.1. Polyglutamine diseases

There are nine different polyglutamine diseases, all characterized by abnormal expansion of a polyglutamine tract in a specific protein. The most common and best studied of these, HD, is caused by aggregate-prone mutant forms of the protein huntingtin having a polyglutamine tract of more than 37 glutamines. The disorder involves neuronal loss in the striatum and cortex leading to gradual loss of voluntary movement coordination and eventually death of the patient. Longer polyglutamine tracts in huntingtin correlate with earlier onset of the disease and higher aggregate propensity of the mutant proteins [34]. Mutant full-length huntingtin and N-terminal fragments thereof aggregate and become substrates for autophagy [97–99]. Moreover, expression of aggregate-prone mutant huntingtin has been found to increase autophagy in HD mouse models and patients [100–102]. This induction of autophagy can be explained by decreased mTOR activity and eIF2 $\alpha$  phosphorylation [103,104]. Importantly, autophagy is specifically important for the degradation of aggregate-prone mutant huntingtin and not wild-type soluble huntingtin [97]. Another aggregate-prone polyglutamine protein, ataxin-3, causing spinocerebellar ataxia type 3 (Machado-Joseph disease), was also found to be degraded by autophagy [105].

Another type of ataxia (lack of muscle control or coordination) is caused by the polyglutamine disease protein ataxin-1, which forms aggregates in the nucleus. Polyglutamine expanded versions of ataxin-1 are the etiological factors of spinocerebellar ataxia 1 (SCA1). If and how nuclear aggregates are degraded by autophagy is currently debated in the field. Proteasomes are present in the cell nucleus, but lysosomes are not. Huntingtin is also found in the nucleus, and aggregate-prone mutant versions of huntingtin must be exported to the cytoplasm to be degraded by autophagy. As described above, this might be regulated by acetylation and phosphorylation of huntingtin [89,90]. Autophagy has been shown to eliminate cytoplasmic polyglutamine-containing aggregates more efficiently than nuclear aggregates [106] and this differential efficiency of degradation could explain why nuclear aggregates are more cytotoxic than cytoplasmic ones.

### 5.2. Parkinson's disease

PD results from loss of dopamine-producing neurons causing tremor, rigidity and impaired balance and coordination. Autophagy has been found to be elevated in PD patient neurons [107]. PD is characterized by the formation of neuronal aggregates called Lewy bodies. The major protein constituent of these Lewy bodies is  $\alpha$ -synuclein, which can be degraded by the proteasome, macroautophagy and CMA [108,109]. A30P and A53T mutations of  $\alpha$ -synuclein cause familial forms of PD [110]. These mutant proteins were shown to bind the CMA receptor lysosomal associated membrane protein type 2A (LAMP-2A) on the lysosomal membrane, blocking their uptake by CMA and inhibiting their own degradation as well as that of other substrates [109].  $\alpha$ -Synuclein undergoes different types of posttranslational modifications, including dopamine-modification, which also inhibits the CMA-mediated degradation of itself and other substrates [111].

### 5.3. FTD and amyotrophic lateral sclerosis (ALS)

Dysfunction of the autophagic machinery can also cause neurodegenerative disease. FTD is the most common form of presenile dementia after AD, characterized by shrinking of the frontal and temporal anterior lobes of the brain and either tau or ubiquitin neuropathology [112]. ALS is a fatal disease characterized by death of motor neurons, resulting in the inability of the brain to control voluntary muscle movement being lost. Both diseases are associ-

ated with ubiquitinated protein inclusions, formed by proteins like tau, TDP-43 or SOD1, that also contain p62 [113]. Rare mutations in the ESCRT subunit CHMP2B are associated with FTD and ALS in patients [114,115]. Individual deletion of several ESCRT components resulted in accumulation of non-degradative autophagosomes in nematodes, flies or mammals [116]. Additionally, reduced ESCRT function in a fly model for HD aggravated polyglutamine-induced neurotoxicity [21]. Furthermore, accumulation of ubiquitinated protein aggregates was observed in cortical neurons of mice [19] or in HeLa cells [17], expressing mutant CHMP2B. This mutation corresponds to a rare patient mutation found in FTD patients, underlining the importance of functional MVBs for proper autophagic maturation and showing that a functional ESCRT machinery is physiologically important for autophagy in mammals.

Point mutations of the p150 subunit of dynactin have also been described in ALS patients [117]. Dynactin is essential for dynamin-dependent transport on microtubules and as discussed above, dynein function is important for autophagosome-lysosome fusion. Dyneins are also mutated in some forms of motor neuron disease and protein aggregation is present in some of these conditions, possibly as an effect of compromised autophagy [33]. Indeed, mutations in the dynein machinery impair autophagic clearance of aggregate-prone proteins and enhance their toxicity in fly and mouse neurodegenerative models [118].

Finally, mutations in the hexameric chaperone p97/VCP cause a dominantly inherited disease known as inclusion-body myopathy with Paget's disease of the bone and frontotemporal dementia (IBMPFD), characterized by nuclear and cytoplasmic aggregates in the brain and muscles of the patient [119]. The appearance of aggregates has previously been thought to result from compromised shuttling of ER associated degradation (ERAD) substrates to the proteasome [120]. However, p97/VCP was recently implicated in autophagy and compromised autophagy might contribute to the symptoms observed in IBMPFD [121]. Interestingly, mutations in p62 are also known to cause Paget's disease of the bone, although it is not known if this is linked to the role of p62 in autophagy or rather its involvement in other signalling pathways [53].

### 5.4. Alzheimer disease

Autophagosomes and autolysosomes have been found to accumulate in dystrophic neurites of AD patients [122]. AD is the most common form of dementia, starting with memory loss and confusion, gradually leading to behaviour and personality changes and eventually severe loss of mental function. AD is associated with formation of extracellular plaques consisting of aggregated amyloid- $\beta$  (A $\beta$ ) peptide and intracellular neurofibrillar tangles composed of hyperphosphorylated tau. The A $\beta$  peptide is formed by cleavage of the membrane protein amyloid precursor protein (APP) by the enzymes  $\beta$ - and  $\gamma$ -secretase.  $\gamma$ -Secretase and A $\beta$  itself has been found within autophagosomes, suggesting autophagosomes to be a site of A $\beta$  production [123]. Indeed, A $\beta$  levels increase upon induction of autophagy. The produced A $\beta$  would normally be degraded in the lysosome [124], but the increased formation of autophagosomes combined with impeded turnover of these vesicles creates favourable conditions for A $\beta$  accumulation and appearance of AD symptoms [123].

### 5.5. Mallory-Denk bodies (MDBs) in chronic liver diseases

Diseases that involve ubiquitinated protein aggregates are not only neurodegenerative. There are also examples of ubiquitinated protein aggregates found in muscle and liver disease. In the liver, MDBs are found in patients with diverse chronic liver diseases, including alcoholic and non-alcoholic steatohepatitis [125]. MDBs



are intermediate filament (IF)-related aggregates. IFs are components of the cytoskeleton composed of different types of proteins and are involved in the maintenance of cell shape, locomotion and intracellular trafficking. Pathophysiologically, aggregation of several different IF subunits is associated with human disease [126]. IFs are also regularly found in aggresomes [31]. MDBs are composed of aggregated abnormal keratins and p62 is found to be required for their formation in cell culture [127]. By immunohistochemistry it was shown that MDBs are also positive for NBR1 [46]. Autophagy was found to be increased in a mouse model of MDBs and further induction of autophagy by rapamycin increased the clearance of these aggregates [128].

In summary, the different types of disease-associated protein aggregates mentioned are substrates for autophagy. Some aggregates are also formed due to autophagic dysfunction. The degradation of these disease-associated aggregates depends on p62 and the core autophagic machinery. Consequently, by learning more about the mechanisms of autophagic degradation of one type of aggregates, the knowledge can likely be applied to several types of aggregates.

## 6. Treating protein aggregate associated diseases by manipulating autophagy?

The neurodegenerative phenotype of diseases involving aggregate-prone proteins seems to depend on the continuous presence of the mutant protein. Neurodegenerative symptoms in a mouse HD model have been shown to be alleviated by direct RNA interference targeting the mutant huntingtin [129]. Interestingly, halting expression of the mutant aggregate-prone protein in symptomatic mice was found to cause disappearance of the inclusions and a complete reversal of the neurodegenerative symptoms in mouse models of HD and SCA1 [130,131]. Therefore it is postulated that removing the aggregate-prone proteins would cure patients of neurodegenerative symptoms. The removal could happen either by stopping the expression of the aggregate-prone protein or enhancing its degradation. As we have seen, autophagy can degrade protein aggregates. Thus, induction of autophagy could be envisaged as a treatment option for patients suffering from protein aggregate associated diseases, provided that there is no downstream block in the autophagy pathway. If such a block at the lysosome level exists, increasing autophagy may actually aggravate the condition.

Expression of autophagy genes has also been seen to decrease with ageing, simultaneous with an increase in intracellular, ubiquitinated protein aggregates [50,132]. Most protein aggregate associated diseases are also late-onset [133]. The decrease in autophagic activity with age would probably aggravate the disease state by reduced clearance of the aggregate-prone proteins. Fruit fly experiments showed that genetic promotion of autophagy in the brain of adult flies reduced the amount of oxidized and ubiquitinated protein species [50]. These effects were also accompanied by increased fly lifespan.

Gene therapy in humans is not an immediate option for treating neurodegenerative diseases by inducing autophagy. However, autophagy can also be induced by drugs. The mTOR inhibitor rapamycin is frequently experimentally used to induce autophagy and is currently in clinical use, although not specifically to induce autophagy [33]. Ravikumar and colleagues showed that mTOR inhibition induced autophagy and reduced toxicity of mutant aggregate-prone huntingtin in fruit fly and mouse HD models [103]. Actually, mTOR inhibition through rapamycin treatment alleviates toxicity of different aggregate-prone proteins, including those found in polyglutamine diseases, PD and some forms of FTD [134]. The treatment with rapamycin reduces the levels of

both soluble and aggregated proteins. An additional cytoprotective effect of rapamycin is that it protects the cells against apoptotic insults, probably through increased removal of mitochondria by mitophagy [135]. However, mTOR controls many other pathways in addition to autophagy and long-term use of rapamycin brings certain side effects, like immunosuppression (this effect is used to prevent rejection of the transplant in renal transplant patients). Thus inducing autophagy without inhibiting mTOR would be desirable. mTOR-independent autophagy pathways and drugs have been described [136,137]. For instance, lithium induces autophagy by reducing intracellular inositol levels [138]. Additionally, increased efficiency of autophagy induction can be expected by combining mTOR inhibition through rapamycin analogues with mTOR-independent small molecule enhancers [139]. However, keeping in mind the problems associated with accumulation of autophagosomes in AD, it is important not only to induce autophagy, but to ensure proper flux throughout the autophagic pathway.

In addition to general activation of the autophagy pathway, specific degradation of aggregate-prone proteins could be envisaged by enhancing the posttranslational modifications that promote their degradation. For instance, enhancing acetylation of mutant huntingtin improves its degradation by autophagy and reverses the toxic effects in primary striatal and cortical neurons [89]. HDAC inhibitors might be used to enhance acetylation in general. We are, however, currently not aware of any direct agent to enhance the specific acetylation of mutant huntingtin, but discovery of drugs that enhance this or other posttranslational modifications that promote clearance of aggregate-prone proteins could benefit future patients.

## 7. Concluding remarks

From the initial idea of a random non-selective process, autophagy has emerged as a collection of many selective pathways targeting specific cargo for degradation. Moreover, autophagy has been established as an alternative pathway to the UPS for degradation of ubiquitinated proteins, specializing in the degradation of aggregate-prone proteins. This degradation requires the autophagy receptors p62 and NBR1 that are also found to localize to various protein aggregates associated with human diseases. In general, inducing autophagy seems to promote aggregate clearance and alleviate the cytotoxic effects of aggregate-prone proteins across many of these diseases, although imbalance in the autophagic flux can be harmful. To develop better tools to enhance degradation of aggregate-prone proteins by autophagy and potentially employ these in therapy, we need greater insight into the mechanisms governing how these proteins are targeted for autophagic degradation.

## Acknowledgements

H.K. is supported by grants from EMBIO, University of Oslo. A.S. is supported by grants from the Norwegian Cancer Society and the Research Council of Norway.

## References

- [1] Verhoef, L.G., Lindsten, K., Masucci, M.G. and Dantuma, N.P. (2002) Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. *Human Mol. Genet.* 11, 2689–2700.
- [2] Stefanis, L., Larsen, K.E., Rideout, H.J., Sulzer, D. and Greene, L.A. (2001) Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. *J. Neurosci.* 21, 9549–9560.
- [3] Massey, A.C., Zhang, C. and Cuervo, A.M. (2006) Chaperone-mediated autophagy in aging and disease. *Curr. Top. Dev. Biol.* 73, 205–235.
- [4] Xie, Z. and Klionsky, D.J. (2007) Autophagosome formation: core machinery and adaptations. *Nat. Cell Biol.* 9, 1102–1109.



- [5] Klionsky, D.J., Cregg, J.M., Dunn Jr., W.A., Emr, S.D., Sakai, Y., Sandoval, I.V., Sibirny, A., Subramani, S., Thumm, M., Veenhuis, M. and Ohsumi, Y. (2003) A unified nomenclature for yeast autophagy-related genes. *Dev. Cell* 5, 539–545.
- [6] Mizushima, N., Levine, B., Cuervo, A.M. and Klionsky, D.J. (2008) Autophagy fights disease through cellular self-digestion. *Nature* 451, 1069–1075.
- [7] Levine, B. and Kroemer, G. (2008) Autophagy in the pathogenesis of disease. *Cell* 132, 27–42.
- [8] Simonsen, A. and Tooze, S.A. (2009) Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes. *J. Cell Biol.* 186, 773–782.
- [9] Longatti, A. and Tooze, S.A. (2009) Vesicular trafficking and autophagosome formation. *Cell Death Differ.* 16, 956–965.
- [10] Jung, C.H., Ro, S.H., Cao, J., Otto, N.M. and Kim, D.H. (2010) mTOR regulation of autophagy. *FEBS Lett.* 584, 1287–1295.
- [11] Axe, E.L., Walker, S.A., Manifava, M., Chandra, P., Roderick, H.L., Habermann, A., Griffiths, G. and Ktistakis, N.T. (2008) Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum. *J. Cell Biol.* 182, 685–701.
- [12] Ohsumi, Y. and Mizushima, N. (2004) Two ubiquitin-like conjugation systems essential for autophagy. *Semin. Cell Dev. Biol.* 15, 231–236.
- [13] Hanada, T., Noda, N.N., Satomi, Y., Ichimura, Y., Fujioka, Y., Takao, T., Inagaki, F. and Ohsumi, Y. (2007) The Atg12–Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy. *J. Biol. Chem.* 282, 37298–37302.
- [14] Fujita, N., Itoh, T., Omori, H., Fukuda, M., Noda, T. and Yoshimori, T. (2008) The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy. *Mol. Biol. Cell* 19, 2092–2100.
- [15] Nakatogawa, H., Ichimura, Y. and Ohsumi, Y. (2007) Atg8, a ubiquitin-like protein required for autophagosome formation, mediates membrane tethering and hemifusion. *Cell* 130, 165–178.
- [16] Gordon, P.B. and Seglen, P.O. (1988) Prelysosomal convergence of autophagic and endocytic pathways. *Biochem. Biophys. Res. Commun.* 151, 40–47.
- [17] Filimonenko, M., Stuffers, S., Raiborg, C., Yamamoto, A., Malerod, L., Fisher, E.M., Isaacs, A., Brech, A., Stenmark, H. and Simonsen, A. (2007) Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease. *J. Cell Biol.* 179, 485–500.
- [18] Razi, M., Chan, E.Y. and Tooze, S.A. (2009) Early endosomes and endosomal coatome are required for autophagy. *J. Cell Biol.* 185, 305–321.
- [19] Lee, J.A., Beigneux, A., Ahmad, S.T., Young, S.G. and Gao, F.B. (2007) ESCRT-III dysfunction causes autophagosome accumulation and neurodegeneration. *Curr. Biol.* 17, 1561–1567.
- [20] Dunn Jr., W.A. (1990) Studies on the mechanisms of autophagy: maturation of the autophagic vacuole. *J. Cell Biol.* 110, 1935–1945.
- [21] Rusten, T.E., Vaccari, T., Lindmo, K., Rodahl, L.M., Nezis, I.P., Sem-Jacobsen, C., Wendler, F., Vincent, J.P., Brech, A., Bilder, D. and Stenmark, H. (2007) ESCRTs and Fab1 regulate distinct steps of autophagy. *Curr. Biol.* 17, 1817–1825.
- [22] de, L.J., Polson, H., Feldman, M., Shokat, K., Tooze, S.A., Urbe, S. and Clague, M.J. (2009) PIKfyve regulation of endosome-linked pathways. *Traffic* 10, 883–893.
- [23] Kimura, S., Noda, T. and Yoshimori, T. (2008) Dynein-dependent movement of autophagosomes mediates efficient encounters with lysosomes. *Cell Struct. Funct.* 33, 109–122.
- [24] Fass, E., Shvets, E., Degani, I., Hirschberg, K. and Elazar, Z. (2006) Microtubules support production of starvation-induced autophagosomes but not their targeting and fusion with lysosomes. *J. Biol. Chem.* 281, 36303–36316.
- [25] Jahreiss, L., Menzies, F.M. and Rubinsztein, D.C. (2008) The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes. *Traffic* 9, 574–587.
- [26] Liang, C., Lee, J.S., Inn, K.S., Gack, M.U., Li, Q., Roberts, E.A., Vergne, I., Deretic, V., Feng, P., Akazawa, C. and Jung, J.U. (2008) Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking. *Nat. Cell Biol.* 10, 776–787.
- [27] Gutierrez, M.G., Munafo, D.B., Beron, W. and Colombo, M.I. (2004) Rab7 is required for the normal progression of the autophagic pathway in mammalian cells. *J. Cell Sci.* 117, 2687–2697.
- [28] Jager, S., Bucci, C., Tanida, I., Ueno, T., Kominami, E., Saftig, P. and Eskelinen, E.L. (2004) Role for Rab7 in maturation of late autophagic vacuoles. *J. Cell Sci.* 117, 4837–4848.
- [29] Fader, C.M., Sanchez, D., Furlan, M. and Colombo, M.I. (2008) Induction of autophagy promotes fusion of multivesicular bodies with autophagic vacuoles in k562 cells. *Traffic* 9, 230–250.
- [30] Pankiv, S., Alemu, E.A., Brech, A., Bruun, J.A., Lamark, T., Overvatn, A., Bjorkoy, G. and Johansen, T. (2010) FYCO1 is a Rab7 effector that binds to LC3 and PI3P to mediate microtubule plus end-directed vesicle transport. *J. Cell Biol.* 188, 253–269.
- [31] Kopito, R.R. (2000) Aggresomes, inclusion bodies and protein aggregation. *Trends Cell Biol.* 10, 524–530.
- [32] Wong, E.S., Tan, J.M., Soong, W.E., Hussein, K., Nukina, N., Dawson, V.L., Dawson, T.M., Cuervo, A.M. and Lim, K.L. (2008) Autophagy-mediated clearance of aggresomes is not a universal phenomenon. *Human Mol. Genet.* 17, 2570–2582.
- [33] Rubinsztein, D.C. (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. *Nature* 443, 780–786.
- [34] Perutz, M.F. and Windle, A.H. (2001) Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. *Nature* 412, 143–144.
- [35] Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R. and Finkbeiner, S. (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. *Nature* 431, 805–810.
- [36] Takahashi, T., Kikuchi, S., Katada, S., Nagai, Y., Nishizawa, M. and Onodera, O. (2008) Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. *Human Mol. Genet.* 17, 345–356.
- [37] Rideout, H.J., Lang-Rollin, I. and Stefanis, L. (2004) Involvement of macroautophagy in the dissolution of neuronal inclusions. *Int. J. Biochem. Cell Biol.* 36, 2551–2562.
- [38] Filimonenko, M., Isakson, P., Finley, K., Anderson, M., Jeong, H., Melia, T.J., Bartlett, B.J., Myers, K., Birkeland, H.C., Lamark, T., Krainc, D., Brech, A., Stenmark, H., Simonsen, A. and Yamamoto, A. (2010) The selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein Alf1. *Mol. Cell* 38, 265–279.
- [39] Kopitz, J., Kisen, G.O., Gordon, P.B., Bohley, P. and Seglen, P.O. (1990) Nonselective autophagy of cytosolic enzymes by isolated rat hepatocytes. *J. Cell Biol.* 111, 941–953.
- [40] Overbye, A., Fengsrud, M. and Seglen, P.O. (2007) Proteomic analysis of membrane-associated proteins from rat liver autophagosomes. *Autophagy* 3, 300–322.
- [41] Lynch-Day, M.A. and Klionsky, D.J. (2010) The Cvt pathway as a model for selective autophagy. *FEBS Lett.* 584, 1359–1366.
- [42] Thurston, T.L., Ryzhakov, G., Bloor, S., von, M.N. and Randow, F. (2009) The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria. *Nat. Immunol.* 10, 1215–1221.
- [43] Novak, I., Kirkin, V., McEwan, D.G., Zhang, J., Wild, P., Rozenknop, A., Rogov, P., Lohr, F., Popovic, D., Occhipinti, A., Reichert, A.S., Terzic, J., Dotsch, V., Ney, P.A. and Dikic, I. (2010) Nix is a selective autophagy receptor for mitochondrial clearance. *EMBO Rep.* 11, 45–51.
- [44] Pankiv, S., Clausen, T.H., Lamark, T., Brech, A., Bruun, J.A., Outzen, H., Overvatn, A., Bjorkoy, G. and Johansen, T. (2007) p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. *J. Biol. Chem.* 282, 24131–24145.
- [45] Bjorkoy, G., Lamark, T., Brech, A., Outzen, H., Perander, M., Overvatn, A., Stenmark, H. and Johansen, T. (2005) p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. *J. Cell Biol.* 171, 603–614.
- [46] Kirkin, V., Lamark, T., Sou, Y.S., Bjorkoy, G., Nunn, J.L., Bruun, J.A., Shvets, E., McEwan, D.G., Clausen, T.H., Wild, P., Bilusic, I., Theurillat, J.P., Overvatn, A., Ishii, T., Elazar, Z., Komatsu, M., Dikic, I. and Johansen, T. (2009) A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. *Mol. Cell* 33, 505–516.
- [47] Hara, T., Nakamura, K., Matsui, M., Yamamoto, A., Nakahara, Y., Suzuki-Migishima, R., Yokoyama, M., Mishima, K., Saito, I., Okano, H. and Mizushima, N. (2006) Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. *Nature* 441, 885–889.
- [48] Komatsu, M., Waguri, S., Chiba, T., Murata, S., Iwata, J., Tanida, I., Ueno, T., Koike, M., Uchiyama, Y., Kominami, E. and Tanaka, K. (2006) Loss of autophagy in the central nervous system causes neurodegeneration in mice. *Nature* 441, 880–884.
- [49] Lindmo, K., Brech, A., Finley, K.D., Gaumer, S., Contamine, D., Rusten, T.E. and Stenmark, H. (2008) The PI3-kinase regulator Vps15 is required for autophagic clearance of protein aggregates. *Autophagy* 4, 500–506.
- [50] Simonsen, A., Cumming, R.C., Brech, A., Isakson, P., Schubert, D.R. and Finley, K.D. (2008) Promoting basal levels of autophagy in the nervous system enhances longevity and oxidant resistance in adult *Drosophila*. *Autophagy* 4, 176–184.
- [51] Nezis, I.P., Simonsen, A., Sagana, A.P., Finley, K., Gaumer, S., Contamine, D., Rusten, T.E., Stenmark, H. and Brech, A. (2008) Ref(2)P, the *Drosophila* melanogaster homologue of mammalian p62, is required for the formation of protein aggregates in adult brain. *J. Cell Biol.* 180, 1065–1071.
- [52] Yamamoto, A., Cremona, M.L. and Rothman, J.E. (2006) Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. *J. Cell Biol.* 172, 719–731.
- [53] Lamark, T., Kirkin, V., Dikic, I. and Johansen, T. (2009) NBR1 and p62 as cargo receptors for selective autophagy of ubiquitinated targets. *Cell Cycle* 8, 1986–1990.
- [54] Pohl, C. and Jentsch, S. (2009) Midbody ring disposal by autophagy is a post-abscission event of cytokinesis. *Nat. Cell Biol.* 11, 65–70.
- [55] Zheng, Y.T., Shahnazari, S., Brech, A., Lamark, T., Johansen, T. and Brumell, J.H. (2009) The adaptor protein p62/SQSTM1 targets invading bacteria to the autophagy pathway. *J. Immunol.* 183, 5909–5916.
- [56] Moscat, J. and Diaz-Meco, M.T. (2009) p62 at the crossroads of autophagy, apoptosis, and cancer. *Cell* 137, 1001–1004.
- [57] Komatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., Sou, Y.S., Ueno, I., Sakamoto, A., Tong, K.L., Kim, M., Nishito, Y., Iemura, S.I., Natsume, T., Ueno, T., Kominami, E., Motohashi, H., Tanaka, K. and Yamamoto, M. (2010) The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. *Nat. Cell Biol.* 12, 1–11.
- [58] Lelouard, H., Gatti, E., Cappello, F., Gresser, O., Camosseto, V. and Pierre, P. (2002) Transient aggregation of ubiquitinated proteins during dendritic cell maturation. *Nature* 417, 177–182.

- [59] Szeto, J., Kaniuk, N.A., Canadien, V., Nisman, R., Mizushima, N., Yoshimori, T., Bazett-Jones, D.P. and Brumell, J.H. (2006) ALIS are stress-induced protein storage compartments for substrates of the proteasome and autophagy. *Autophagy* 2, 189–199.
- [60] Lelouard, H., Ferrand, V., Marguet, D., Bania, J., Camosseto, V., David, A., Gatti, E. and Pierre, P. (2004) Dendritic cell aggresome-like induced structures are dedicated areas for ubiquitination and storage of newly synthesized defective proteins. *J. Cell Biol.* 164, 667–675.
- [61] Komatsu, M., Waguri, S., Ueno, T., Iwata, J., Murata, S., Tanida, I., Ezaki, J., Mizushima, N., Ohsumi, Y., Uchiyama, Y., Kominami, E., Tanaka, K. and Chiba, T. (2005) Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. *J. Cell Biol.* 169, 425–434.
- [62] Komatsu, M., Waguri, S., Koike, M., Sou, Y.S., Ueno, T., Hara, T., Mizushima, N., Iwata, J., Ezaki, J., Murata, S., Hamazaki, J., Nishito, Y., Iemura, S., Natsume, T., Yanagawa, T., Uwayama, J., Warabi, E., Yoshida, H., Ishii, T., Kobayashi, A., Yamamoto, M., Yue, Z., Uchiyama, Y., Kominami, E. and Tanaka, K. (2007) Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. *Cell* 131, 1149–1163.
- [63] Korolchuk, V.I., Mansilla, A., Menzies, F.M. and Rubinsztein, D.C. (2009) Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. *Mol. Cell* 33, 517–527.
- [64] Juhasz, G., Erdi, B., Sass, M. and Neufeld, T.P. (2007) Atg7-dependent autophagy promotes neuronal health, stress tolerance, and longevity but is dispensable for metamorphosis in *Drosophila*. *Genes Dev.* 21, 3061–3066.
- [65] Zatloukal, K., Stumpfner, C., Fuchsichler, A., Heid, H., Schnoelzer, M., Kenner, L., Kleinert, R., Prinz, M., Aguzzi, A. and Denk, H. (2002) p62 is a common component of cytoplasmic inclusions in protein aggregation diseases. *Am. J. Pathol.* 160, 255–263.
- [66] Kuusisto, E., Salminen, A. and Alafuzoff, I. (2001) Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. *Neuroreport* 12, 2085–2090.
- [67] Kuusisto, E., Kauppinen, T. and Alafuzoff, I. (2008) Use of p62/SQSTM1 antibodies for neuropathological diagnosis. *Neuropathol. Appl. Neurobiol.* 34, 169–180.
- [68] Simonsen, A., Birkeland, H.C., Gillooly, D.J., Mizushima, N., Kuma, A., Yoshimori, T., Slagsvold, T., Brech, A. and Stenmark, H. (2004) Alf1, a novel FYVE-domain-containing protein associated with protein granules and autophagic membranes. *J. Cell Sci.* 117, 4239–4251.
- [69] Clausen, T.H., Lamark, T., Isakson, P., Finley, K., Larsen, K.E., Brech, A., Overvatn, A., Stenmark, H., Simonsen, A. and Johansen, T. (2010) p62/SQSTM1 and ALFY interact to facilitate the formation of p62 bodies/ALIS and their degradation by autophagy. *Autophagy* 6, 330–344.
- [70] Finley, K.D., Edeen, P.T., Cumming, R.C., Mardahl-Dumesnil, M.D., Taylor, B.J., Rodriguez, M.H., Hwang, C.E., Benedetti, M. and McKeown, M. (2003) Blue cheese mutations define a novel, conserved gene involved in progressive neural degeneration. *J. Neurosci.* 23, 1254–1264.
- [71] Pandey, U.B., Nie, Z., Batlevi, Y., McCray, B.A., Ritson, G.P., Nedelsky, N.B., Schwartz, S.L., DiProspero, N.A., Knight, M.A., Schuldiner, O., Padmanabhan, R., Hild, M., Berry, D.L., Garza, D., Hubbert, C.C., Yao, T.P., Baehrecke, E.H. and Taylor, J.P. (2007) HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. *Nature* 447, 859–863.
- [72] Iwata, A., Riley, B.E., Johnston, J.A. and Kopito, R.R. (2005) HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. *J. Biol. Chem.* 280, 40282–40292.
- [73] Rodriguez-Gonzalez, A., Lin, T., Ikeda, A.K., Simms-Waldrup, T., Fu, C. and Sakamoto, K.M. (2008) Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. *Cancer Res.* 68, 2557–2560.
- [74] Kawaguchi, Y., Kovacs, J.J., McLaurin, A., Vance, J.M., Ito, A. and Yao, T.P. (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. *Cell* 115, 727–738.
- [75] Lee, J.Y., Koga, H., Kawaguchi, Y., Tang, W., Wong, E., Gao, Y.S., Pandey, U.B., Kaushik, S., Tresse, E., Lu, J., Taylor, J.P., Cuervo, A.M. and Yao, T.P. (2010) HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. *EMBO J.* 29, 969–980.
- [76] Scherz-Shouval, R., Shvets, E., Fass, E., Shorer, H., Gil, L. and Elazar, Z. (2007) Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. *EMBO J.* 26, 1749–1760.
- [77] Terry, L.J., Shows, E.B. and Wente, S.R. (2007) Crossing the nuclear envelope: hierarchical regulation of nucleocytoplasmic transport. *Science* 318, 1412–1416.
- [78] Liang, X.H., Yu, J., Brown, K. and Levine, B. (2001) Beclin 1 contains a leucine-rich nuclear export signal that is required for its autophagy and tumor suppressor function. *Cancer Res.* 61, 3443–3449.
- [79] Liang, X.H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, H. and Levine, B. (1999) Induction of autophagy and inhibition of tumorigenesis by Beclin 1. *Nature* 402, 672–676.
- [80] Mauvezin, C., Orpinell, M., Francis, V.A., Mansilla, F., Duran, J., Ribas, V., Palacin, M., Boya, P., Teleman, A.A. and Zorzano, A. (2010) The nuclear cofactor DOR regulates autophagy in mammalian and *Drosophila* cells. *EMBO Rep.* 11, 37–44.
- [81] Pankiv, S., Lamark, T., Bruun, J.A., Overvatn, A., Bjorkoy, G. and Johansen, T. (2010) Nucleocytoplasmic shuttling of p62/SQSTM1 and its role in recruitment of nuclear polyubiquitinated proteins to promyelocytic leukemia bodies. *J. Biol. Chem.* 285, 5941–5953.
- [82] Bernardi, R. and Pandolfi, P.P. (2007) Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. *Nat. Rev. Mol. Cell Biol.* 8, 1006–1016.
- [83] Rockel, T.D., Stuhlmann, D. and von, M.A. (2005) Proteasomes degrade proteins in focal subdomains of the human cell nucleus. *J. Cell Sci.* 118, 5231–5242.
- [84] Wooten, M.W., Geetha, T., Babu, J.R., Seibenhener, M.L., Peng, J., Cox, N., Diaz-Meco, M.T. and Moscat, J. (2008) Essential role of sequestosome 1/p62 in regulating accumulation of Lys63-ubiquitinated proteins. *J. Biol. Chem.* 283, 6783–6789.
- [85] Long, J., Gallagher, T.R., Cavey, J.R., Sheppard, P.W., Ralston, S.H., Layfield, R. and Searle, M.S. (2008) Ubiquitin recognition by the ubiquitin-associated domain of p62 involves a novel conformational switch. *J. Biol. Chem.* 283, 5427–5440.
- [86] Tan, J.M., Wong, E.S., Kirkpatrick, D.S., Pletnikova, O., Ko, H.S., Tay, S.P., Ho, M.W., Troncoso, J., Gygi, S.P., Lee, M.K., Dawson, V.L., Dawson, T.M. and Lim, K.L. (2008) Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. *Human Mol. Genet.* 17, 431–439.
- [87] Olzmann, J.A., Li, L., Chudaev, M.V., Chen, J., Perez, F.A., Palmiter, R.D. and Chin, L.S. (2007) Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. *J. Cell Biol.* 178, 1025–1038.
- [88] Kim, P.K., Hailey, D.W., Mullen, R.T. and Lippincott-Schwartz, J. (2008) Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes. *Proc. Natl. Acad. Sci. USA* 105, 20567–20574.
- [89] Jeong, H., Then, F., Melia Jr., T.J., Mazzulli, J.R., Cui, L., Savas, J.N., Voisine, C., Paganetti, P., Tanese, N., Hart, A.C., Yamamoto, A. and Krainc, D. (2009) Acetylation targets mutant huntingtin to autophagosomes for degradation. *Cell* 137, 60–72.
- [90] Thompson, L.M., Aiken, C.T., Kaltenbach, L.S., Agrawal, N., Illes, K., Khoshnan, A., Martinez-Vincente, M., Arrasate, M., O'Rourke, J.G., Khashwji, H., Lukacovich, T., Zhu, Y.Z., Lau, A.L., Massey, A., Hayden, M.R., Zeitlin, S.O., Finkbeiner, S., Green, K.N., LaFerla, F.M., Bates, G., Huang, L., Patterson, P.H., Lo, D.C., Cuervo, A.M., Marsh, J.L. and Steffan, J.S. (2009) IKK phosphorylates huntingtin and targets it for degradation by the proteasome and lysosome. *J. Cell Biol.* 187, 1083–1099.
- [91] Chen, H.K., Fernandez-Funez, P., Acevedo, S.F., Lam, Y.C., Kaytor, M.D., Fernandez, M.H., Aitken, A., Skoulakis, E.M., Orr, H.T., Botas, J. and Zoghbi, H.Y. (2003) Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. *Cell* 113, 457–468.
- [92] Emamian, E.S., Kaytor, M.D., Duvick, L.A., Zu, T., Tousey, S.K., Zoghbi, H.Y., Clark, H.B. and Orr, H.T. (2003) Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. *Neuron* 38, 375–387.
- [93] Humbert, S., Bryson, E.A., Cordelieres, F.P., Connors, N.C., Datta, S.R., Finkbeiner, S., Greenberg, M.E. and Saudou, F. (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves huntingtin phosphorylation by Akt. *Dev. Cell* 2, 831–837.
- [94] Fei, E., Jia, N., Zhang, T., Ma, X., Wang, H., Liu, C., Zhang, W., Ding, L., Nukina, N. and Wang, G. (2007) Phosphorylation of ataxin-3 by glycogen synthase kinase 3 $\beta$  at serine 256 regulates the aggregation of ataxin-3. *Biochem. Biophys. Res. Commun.* 357, 487–492.
- [95] Schilling, B., Gafni, J., Torcassi, C., Cong, X., Row, R.H., LaFevre-Bernt, M.A., Cusack, M.P., Ratovitski, T., Hirschhorn, R., Ross, C.A., Gibson, B.W. and Ellerby, L.M. (2006) Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity. *J. Biol. Chem.* 281, 23686–23697.
- [96] Luo, S., Vacher, C., Davies, J.E. and Rubinsztein, D.C. (2005) Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. *J. Cell Biol.* 169, 647–656.
- [97] Ravikumar, B., Duden, R. and Rubinsztein, D.C. (2002) Aggregate-prone proteins with polyglutamine and polyaniline expansions are degraded by autophagy. *Human Mol. Genet.* 11, 1107–1117.
- [98] Qin, Z.H., Wang, Y., Kegel, K.B., Kazantsev, A., Apostol, B.L., Thompson, L.M., Yoder, J., Aronin, N. and Difiglia, M. (2003) Autophagy regulates the processing of amino terminal huntingtin fragments. *Human Mol. Genet.* 12, 3231–3244.
- [99] Shibata, M., Lu, T., Furuya, T., Degterev, A., Mizushima, N., Yoshimori, T., MacDonald, M., Yankner, B. and Yuan, J. (2006) Regulation of intracellular accumulation of mutant huntingtin by Beclin 1. *J. Biol. Chem.* 281, 14474–14485.
- [100] Kegel, K.B., Kim, M., Sapp, E., McIntyre, C., Castano, J.G., Aronin, N. and Difiglia, M. (2000) Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. *J. Neurosci.* 20, 7268–7278.
- [101] Petersen, A., Larsen, K.E., Behr, G.G., Romero, N., Przedborski, S., Brundin, P. and Sulzer, D. (2001) Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. *Human Mol. Genet.* 10, 1243–1254.
- [102] Nagata, E., Sawa, A., Ross, C.A. and Snyder, S.H. (2004) Autophagosome-like vacuole formation in Huntington's disease lymphoblasts. *Neuroreport* 15, 1325–1328.
- [103] Ravikumar, B., Vacher, C., Berger, Z., Davies, J.E., Luo, S., Oroz, L.G., Scaravilli, F., Easton, D.F., Duden, R., O'Kane, C.J. and Rubinsztein, D.C. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine

- expansions in fly and mouse models of Huntington disease. *Nat. Genet.* 36, 585–595.
- [104] Kouroku, Y., Fujita, E., Tanida, I., Ueno, T., Isoai, A., Kumagai, H., Ogawa, S., Kaufman, R.J., Kominami, E. and Momoi, T. (2007) ER stress (PERK/eIF2 $\alpha$  phosphorylation) mediates the polyglutamine-induced LC3 conversion, an essential step for autophagy formation. *Cell Death Differ.* 14, 230–239.
- [105] Menzies, F.M., Huebener, J., Renna, M., Bonin, M., Riess, O. and Rubinsztein, D.C. (2010) Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. *Brain* 133, 93–104.
- [106] Iwata, A., Christianson, J.C., Buccini, M., Ellerby, L.M., Nukina, N., Forno, L.S. and Kopito, R.R. (2005) Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. *Proc. Natl. Acad. Sci. USA* 102, 13135–13140.
- [107] Anglade, P., Vyas, S., Javoy-Agid, F., Herrero, M.T., Michel, P.P., Marquez, J., Mouatt-Prigent, A., Ruberg, M., Hirsch, E.C. and Agid, Y. (1997) Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. *Histol. Histopathol.* 12, 25–31.
- [108] Webb, J.L., Ravikumar, B., Atkins, J., Skepper, J.N. and Rubinsztein, D.C. (2003) Alpha-synuclein is degraded by both autophagy and the proteasome. *J. Biol. Chem.* 278, 25009–25013.
- [109] Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T. and Sulzer, D. (2004) Impaired degradation of mutant (alpha)-synuclein by chaperone-mediated autophagy. *Science* 305, 1292–1295.
- [110] Nussbaum, R.L. and Polymeropoulos, M.H. (1997) Genetics of Parkinson's disease. *Human Mol. Genet.* 6, 1687–1691.
- [111] Martinez-Vicente, M., Tallozy, Z., Kaushik, S., Massey, A.C., Mazzulli, J., Mosharov, E.V., Hodara, R., Fredenburg, R., Wu, D.C., Follenzi, A., Dauer, W., Przedborski, S., Ischiropoulos, H., Lansbury, P.T., Sulzer, D. and Cuervo, A.M. (2008) Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. *J. Clin. Invest.* 118, 777–788.
- [112] Neary, D., Snowden, J. and Mann, D. (2005) Frontotemporal dementia. *Lancet Neurol.* 4, 771–780.
- [113] Talbot, K. and Ansorge, O. (2006) Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease. *Human Mol. Genet.* 15 (2), R182–R187.
- [114] Skibinski, G., Parkinson, N.J., Brown, J.M., Chakrabarti, L., Lloyd, S.L., Hummerich, H., Nielsen, J.E., Hodges, J.R., Spillantini, M.G., Thüsgaard, T., Brandner, S., Brun, A., Rossor, M.N., Gade, A., Johannsen, P., Sorensen, S.A., Gydesen, S., Fisher, E.M. and Collinge, J. (2005) Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. *Nat. Genet.* 37, 806–808.
- [115] Parkinson, N., Ince, P.G., Smith, M.O., Highley, R., Skibinski, G., Andersen, P.M., Morrison, K.E., Pall, H.S., Hardiman, O., Collinge, J., Shaw, P.J. and Fisher, E.M. (2006) ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). *Neurology* 67, 1074–1077.
- [116] Rusten, T.E. and Stenmark, H. (2009) How do ESCRT proteins control autophagy? *J. Cell Sci.* 122, 2179–2183.
- [117] Munch, C., Sedlmeier, R., Meyer, T., Homberg, V., Sperfeld, A.D., Kurt, A., Prudlo, J., Peraus, G., Hanemann, C.O., Stumm, G. and Ludolph, A.C. (2004) Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. *Neurology* 63, 724–726.
- [118] Ravikumar, B., Acevedo-Arozena, A., Imarisio, S., Berger, Z., Vacher, C., O'Kane, C.J., Brown, S.D. and Rubinsztein, D.C. (2005) Dynein mutations impair autophagic clearance of aggregate-prone proteins. *Nat. Genet.* 37, 771–776.
- [119] Watts, G.D., Wymer, J., Kovach, M.J., Mehta, S.G., Mumm, S., Darvish, D., Pestronk, A., Whyte, M.P. and Kimonis, V.E. (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. *Nat. Genet.* 36, 377–381.
- [120] Weihl, C.C., Dalal, S., Pestronk, A. and Hanson, P.I. (2006) Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. *Human Mol. Genet.* 15, 189–199.
- [121] Ju, J.S., Fuentealba, R.A., Miller, S.E., Jackson, E., Piwnicka-Worms, D., Baloh, R.H. and Weihl, C.C. (2009) Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. *J. Cell Biol.* 187, 875–888.
- [122] Nixon, R.A., Wegiel, J., Kumar, A., Yu, W.H., Peterhoff, C., Cataldo, A. and Cuervo, A.M. (2005) Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. *J. Neuropathol. Exp. Neurol.* 64, 113–122.
- [123] Nixon, R.A. (2007) Autophagy, amyloidogenesis and Alzheimer disease. *J. Cell Sci.* 120, 4081–4091.
- [124] Yu, W.H., Cuervo, A.M., Kumar, A., Peterhoff, C.M., Schmidt, S.D., Lee, J.H., Mohan, P.S., Mercken, M., Farmery, M.R., Tjernberg, L.O., Jiang, Y., Duff, K., Uchiyama, Y., Naslund, J., Mathews, P.M., Cataldo, A.M. and Nixon, R.A. (2005) Macroautophagy – a novel beta-amyloid peptide-generating pathway activated in Alzheimer's disease. *J. Cell Biol.* 171, 87–98.
- [125] Strnad, P., Zatloukal, K., Stumptner, C., Kulaksiz, H. and Denk, H. (2008) Mallory-Denk bodies: lessons from keratin-containing hepatic inclusion bodies. *Biochim. Biophys. Acta* 1782, 764–774.
- [126] Omary, M.B., Coulombe, P.A. and McLean, W.H. (2004) Intermediate filament proteins and their associated diseases. *New Engl. J. Med.* 351, 2087–2100.
- [127] Stumptner, C., Fuchsichler, A., Zatloukal, K. and Denk, H. (2007) In vitro production of Mallory bodies and intracellular hyaline bodies: the central role of sequestosome 1/p62. *Hepatology* 46, 851–860.
- [128] Harada, M., Hanada, S., Toivola, D.M., Ghorri, N. and Omary, M.B. (2008) Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasome inhibitor-mediated formation. *Hepatology* 47, 2026–2035.
- [129] Harper, S.Q., Staber, P.D., He, X., Eliason, S.L., Martins, I.H., Mao, Q., Yang, L., Kotin, R.M., Paulson, H.L. and Davidson, B.L. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. *Proc. Natl. Acad. Sci. USA* 102, 5820–5825.
- [130] Yamamoto, A., Lucas, J.J. and Hen, R. (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. *Cell* 101, 57–66.
- [131] Zu, T., Duvick, L.A., Kaytor, M.D., Berlinger, M.S., Zoghbi, H.Y., Clark, H.B. and Orr, H.T. (2004) Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. *J. Neurosci.* 24, 8853–8861.
- [132] Cuervo, A.M., Bergamini, E., Brunk, U.T., Droge, W., French, M. and Terman, A. (2005) Autophagy and aging: the importance of maintaining “clean” cells. *Autophagy* 1, 131–140.
- [133] Taylor, J.P., Hardy, J. and Fischbeck, K.H. (2002) Toxic proteins in neurodegenerative disease. *Science* 296, 1991–1995.
- [134] Berger, Z., Ravikumar, B., Menzies, F.M., Oroz, L.G., Underwood, B.R., Pangalos, M.N., Schmitt, I., Wullner, U., Evert, B.O., O'Kane, C.J. and Rubinsztein, D.C. (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. *Human Mol. Genet.* 15, 433–442.
- [135] Ravikumar, B., Berger, Z., Vacher, C., O'Kane, C.J. and Rubinsztein, D.C. (2006) Rapamycin pre-treatment protects against apoptosis. *Human Mol. Genet.* 15, 1209–1216.
- [136] Williams, A., Sarkar, S., Cudde, P., Tfofi, E.K., Saiki, S., Siddiqi, F.H., Jahreiss, L., Fleming, A., Pask, D., Goldsmith, P., O'Kane, C.J., Floto, R.A. and Rubinsztein, D.C. (2008) Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. *Nat. Chem. Biol.* 4, 295–305.
- [137] Sarkar, S., Davies, J.E., Huang, Z., Tunnacliffe, A. and Rubinsztein, D.C. (2007) Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. *J. Biol. Chem.* 282, 5641–5652.
- [138] Sarkar, S., Floto, R.A., Berger, Z., Imarisio, S., Cordenier, A., Pasco, M., Cook, L.J. and Rubinsztein, D.C. (2005) Lithium induces autophagy by inhibiting inositol monophosphatase. *J. Cell Biol.* 170, 1101–1111.
- [139] Sarkar, S., Perlstein, E.O., Imarisio, S., Pineau, S., Cordenier, A., Maglathlin, R.L., Webster, J.A., Lewis, T.A., O'Kane, C.J., Schreiber, S.L. and Rubinsztein, D.C. (2007) Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. *Nat. Chem. Biol.* 3, 331–338.